Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Mar 2009
Price :
$35
*
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Hot flashes; Menopausal syndrome; Menopause; Vasomotor symptoms
- Focus Therapeutic Use
- 01 Jan 2008 Results have been reported.
- 11 May 2007 New trial record.